Erin Lavelle
Net worth: - $ as of 2024-03-30
Career history of Erin Lavelle
Former positions of Erin Lavelle
| Companies | Position | Start | End |
|---|---|---|---|
| ELIEM THERAPEUTICS, INC. | Chief Operating Officer | 2020-09-30 | 2023-03-09 |
| Director of Finance/CFO | 2020-09-30 | 2023-03-09 | |
| ALDER BIOPHARMACEUTICALS, INC. | Chief Operating Officer | 2018-04-15 | 2020-01-31 |
| AMGEN INC. | Corporate Officer/Principal | 2016-05-31 | 2018-02-28 |
| Sales & Marketing | 2003-06-30 | 2016-05-31 | |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Director/Board Member | - | - |
| NEUROGENE INC. | Director/Board Member | 2020-05-31 | - |
| Independent Dir/Board Member | 2020-05-31 | - |
Training of Erin Lavelle
| Yale University | Undergraduate Degree |
Statistics
International
| United States | 6 |
| Canada | 2 |
Operational
| Chief Operating Officer | 2 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Erin Lavelle
- Experience